Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

NCT03895684 is registered in ClinicalTrials.gov with Salarius Pharmaceuticals, LLC as lead sponsor.

NCT NCT03895684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03895684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
Lead sponsor
Salarius Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Completed
Start date
June 25, 2019
Completion date
April 13, 2021
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors